ADARx Pharmaceuticals, Inc.
No SEC Form 4 filings for $ADRX in the last 30 days.
See all $ADRX insider activity →ADARx Pharmaceuticals priced its IPO at $17 per share, raising $446.3M. Shares will trade on Nasdaq under ADRX. AbbVie will invest $100M, owning 4.9% post-IPO. Total proceeds may reach $535.2M. The company focuses on siRNA therapeutics. J.P. Morgan and others lead the offering.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning ADRX (ADARx Pharmaceuticals, Inc.). Coverage has skewed bullish: 4 bullish, 0 neutral, and 0 bearish.
Newly listed biotech offering significant capital for development.
AlphAI scores every news story that mentions ADRX with an AI model for sentiment and relevance, and aggregates insider trades from ADARx Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
ADARx Pharmaceuticals priced its IPO at $17 per share, raising $446.3M. Shares will trade on Nasdaq under ADRX. AbbVie will invest $100M, owning 4.9% post-IPO. Total proceeds may reach $535.2M. The company focuses on siRNA therapeutics. J.P. Morgan and others lead the offering.
2 min read